Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial
Recommended Citation
Gold LS, Papp K, Pariser D, Bhatia N, Sofen H, Albrecht L, Gooderham M, Duffin KC, Chen M, Paris M, Cheng S, Picard H, Wang Y, and Green L. Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. J Am Acad Dermatol 2023; 88(2):430-433.
Document Type
Article
Publication Date
2-2023
Publication Title
Journal of the American Academy of Dermatology
ePublication
ePub ahead of print
Volume
88
Issue
2
First Page
430
Last Page
433
COinS
